A citation-based method for searching scientific literature

Saira Khalique, Christopher J Lord, Susana Banerjee, Rachael Natrajan. Semin Cancer Biol 2020
Times Cited: 4







List of co-cited articles
34 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
155
75

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
141
75

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund,[...]. Lancet Oncol 2012
520
75

Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Brian C Willis, Emily A Sloan, Kristen A Atkins, Mark H Stoler, Anne M Mills. Mod Pathol 2017
28
50

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Hisham Abou-Taleb, Ken Yamaguchi, Noriomi Matsumura, Ryusuke Murakami, Hidekatsu Nakai, Koichiro Higasa, Yasuaki Amano, Kaoru Abiko, Yumiko Yoshioka, Junzo Hamanishi,[...]. Oncotarget 2016
16
50

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Saira Khalique, Kalnisha Naidoo, Ayoma D Attygalle, Divya Kriplani, Frances Daley, Anne Lowe, James Campbell, Thomas Jones, Michael Hubank, Kerry Fenwick,[...]. J Pathol Clin Res 2018
17
50

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
50

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
805
50


BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
665
50

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
892
50

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers.  2017
421
50


ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Jianfeng Shen, Yang Peng, Leizhen Wei, Wei Zhang, Lin Yang, Li Lan, Prabodh Kapoor, Zhenlin Ju, Qianxing Mo, Ie-Ming Shih,[...]. Cancer Discov 2015
209
50

Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Takafumi Kuroda, Hideaki Ogiwara, Mariko Sasaki, Kazuaki Takahashi, Hiroshi Yoshida, Takako Kiyokawa, Kazuki Sudo, Kenji Tamura, Tomoyasu Kato, Aikou Okamoto,[...]. Gynecol Oncol 2019
11
50

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke,[...]. Lancet Oncol 2016
110
50

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Joseph J Caumanns, G Bea A Wisman, Katrien Berns, Ate G J van der Zee, Steven de Jong. Biochim Biophys Acta Rev Cancer 2018
36
50

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Takeshi Fukumoto, Pyoung Hwa Park, Shuai Wu, Nail Fatkhutdinov, Sergey Karakashev, Timothy Nacarelli, Andrew V Kossenkov, David W Speicher, Stephanie Jean, Lin Zhang,[...]. Cell Rep 2018
37
50

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Hideaki Ogiwara, Kazuaki Takahashi, Mariko Sasaki, Takafumi Kuroda, Hiroshi Yoshida, Reiko Watanabe, Ami Maruyama, Hideki Makinoshima, Fumiko Chiwaki, Hiroki Sasaki,[...]. Cancer Cell 2019
67
50

ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Eleftherios P Samartzis, Aurelia Noske, Konstantin J Dedes, Daniel Fink, Patrick Imesch. Int J Mol Sci 2013
83
50

Cancer-Associated Mutations in Endometriosis without Cancer.
Michael S Anglesio, Nickolas Papadopoulos, Ayse Ayhan, Tayyebeh M Nazeran, Michaël Noë, Hugo M Horlings, Amy Lum, Siân Jones, Janine Senz, Tamer Seckin,[...]. N Engl J Med 2017
235
50

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, Annemiek M C Gennissen, Tesa M Severson, Bastiaan Evers, G Bea A Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L Beijersbergen,[...]. Oncogene 2018
33
50


Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan.
H Kobayashi, K Sumimoto, N Moniwa, M Imai, K Takakura, T Kuromaki, E Morioka, K Arisawa, T Terao. Int J Gynecol Cancer 2007
181
50

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
Chris T Williamson, Rowan Miller, Helen N Pemberton, Samuel E Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati,[...]. Nat Commun 2016
142
50


Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Yuriko Uehara, Katsutoshi Oda, Yuji Ikeda, Takahiro Koso, Shingo Tsuji, Shogo Yamamoto, Kayo Asada, Kenbun Sone, Reiko Kurikawa, Chinami Makii,[...]. PLoS One 2015
31
50

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Rowan E Miller, Rachel Brough, Ilirjana Bajrami, Chris T Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan,[...]. Mol Cancer Ther 2016
48
50

Targeting EZH2 in cancer.
Kimberly H Kim, Charles W M Roberts. Nat Med 2016
636
50

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
345
50


Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
578
50

ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Benjamin G Bitler, Shuai Wu, Pyoung Hwa Park, Yang Hai, Katherine M Aird, Yemin Wang, Yali Zhai, Andrew V Kossenkov, Ana Vara-Ailor, Frank J Rauscher,[...]. Nat Cell Biol 2017
103
50

Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study.
Hao-Ting Chang, Mei-Ling Chiu, Tao-Yuean Wang, Tzu-Chien Chen, Chih-Long Chang, Tsung-Hsien Su, Kuo-Gong Wang, Kung-Liahng Wang, Yuh-Cheng Yang, Jen-Ruei Chen. Int J Environ Res Public Health 2020
7
50

Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
335
25

Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.
Alka Singh, Sameer Gupta, Manisha Sachan. Front Cell Dev Biol 2019
17
25

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
879
25

The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Susanna Leskela, Ignacio Romero, Eva Cristobal, Belén Pérez-Mies, Juan M Rosa-Rosa, Ana Gutierrez-Pecharroman, Almudena Santón, Belén O Gonzalez, Raquel López-Reig, David Hardisson,[...]. Am J Surg Pathol 2020
10
25

Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
David S P Tan, Marjan Iravani, W Glenn McCluggage, Maryou B K Lambros, Fernanda Milanezi, Alan Mackay, Charles Gourley, Felipe C Geyer, Radost Vatcheva, Joanne Millar,[...]. Clin Cancer Res 2011
85
25

High grade serous ovarian carcinomas originate in the fallopian tube.
S Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, Noushin Niknafs, Vilmos Adleff, Michael Noe, Rohit Bhattacharya, Marian Novak, Siân Jones, Jillian Phallen,[...]. Nat Commun 2017
234
25

Low-grade serous ovarian cancer: A review.
Anis Kaldawy, Yakir Segev, Ofer Lavie, Ron Auslender, Victoria Sopik, Steven A Narod. Gynecol Oncol 2016
70
25


Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review.
F Chen, K Gaitskell, M J Garcia, A Albukhari, J Tsaltas, A A Ahmed. BJOG 2017
36
25

Breastfeeding and maternal health outcomes: a systematic review and meta-analysis.
Ranadip Chowdhury, Bireshwar Sinha, Mari Jeeva Sankar, Sunita Taneja, Nita Bhandari, Nigel Rollins, Rajiv Bahl, Jose Martines. Acta Paediatr 2015
282
25

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
201
25

SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Michelle Moh, Gregor Krings, Deniz Ates, Anil Aysal, Grace E Kim, Joseph T Rabban. Am J Surg Pathol 2016
62
25

Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Robert A Soslow, Guangming Han, Kay J Park, Karuna Garg, Narciso Olvera, David R Spriggs, Noah D Kauff, Douglas A Levine. Mod Pathol 2012
116
25

The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Susanne Malander, Eva Rambech, Ulf Kristoffersson, Britta Halvarsson, Mona Ridderheim, Ake Borg, Mef Nilbert. Gynecol Oncol 2006
82
25

Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
Melissa K McConechy, Jiarui Ding, Janine Senz, Winnie Yang, Nataliya Melnyk, Alicia A Tone, Leah M Prentice, Kimberly C Wiegand, Jessica N McAlpine, Sohrab P Shah,[...]. Mod Pathol 2014
129
25

Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
Susanna Leskela, Ignacio Romero, Eva Cristobal, Belén Pérez-Mies, Juan M Rosa-Rosa, Ana Gutierrez-Pecharroman, Tamara Caniego-Casas, Almudena Santón, Belén Ojeda, Raquel López-Reig,[...]. Am J Surg Pathol 2020
9
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.